Fig. 7
The m6A/RP11/Zeb1 axis and in vivo progression of CRC. a & b The relative mRNA expression of Zeb1 in two Oncomine datasets: Hong Colorectal (a), and Skrzypczak Colorectal 2 (b). c & d The relative mRNA expression of Zeb1 (c) and Fbxo45 (d) in patients with stage N0, N1, and N2 CRC based on data available from TCGA database. e DFS of CRC patients with high (n = 135) and low (n = 134) levels of RP11 was plotted according to the Kaplan-Meier method. f DFS of CRC patients with high (n = 135) and low (n = 135) levels of RP11/Siah1 was plotted according to the Kaplan-Meier method. g DFS of CRC patients with high (n = 135) and low (n = 135) levels of RP11/Fbxo45 was plotted according to the Kaplan-Meier method. (H) DFS of CRC patients with high (n = 135) and low (n = 134) levels of Zeb1 was plotted according to the Kaplan-Meier method. (I) DFS of CRC patients with high (n = 135) and low (n = 135) levels of Zeb1/Siah1 was plotted according to the Kaplan-Meier method. j DFS of CRC patients with high (n = 135) and low (n = 135) levels of Zeb1/Fbxo45 was plotted according to the Kaplan-Meier method. *p < 0.05, **p < 0.01 compared with control